Karin Seifert PhD
- Karin Seifert's Contacts
- Room 491
- Keppel Street
- WC1E 7HT
- T: ++44 020 7927 2643
I earned a degree in pharmacy from the University of Vienna, Austria, followed by completion of a doctoral degree at the University of Vienna (subject: pharmaceutical chemistry). During this time I worked on the intestinal parasite Entamoeba histolytica and undertook studies on structure activity relationships and mode of action of novel alkylphosphocholines and standard treatment. I joined LSHTM in 2002 as Research Fellow to work on the anti-leishmanial drug miltefosine, followed by promotion to Lecturer in 2008. I have since worked on specific aspects in drug and vaccine development for leishmaniasis. I also hold a Certificate in Pharmacoepidemiology and Pharmacovigilance from LSHTM, which I completed in 2009.
I am module organiser for the in-house MSc module "Antimicrobial Chemotherapy" and deliver a number of lectures and practicals on this theme. I am supervising MSc students during their summer projects and also contribute to DL teaching through material updates and marking.
Research at LSHTM has included work on
- drug discovery and development: specifically i) drug resistance and efficacy, ii) drug activity evaluation and structure activity relationships (SAR), iii) studies on multidrug and combination chemotherapy, iv) investigation of drug delivery systems and v) studies on the role of macrophages in anti-leishmanial drug treatment.
- vaccine development: specifically proof-of-concept studies in an EC funded project to develop a novel DNA vaccine for prophylactic and therapeutic indications in leishmaniasis (LEISHDNAVAX).
- pharmacokinetic / pharmacodynamic relationships of anti-leishmanial drugs and the biological evidence base of translational models used in drug discovery and development.
Recent research support was received from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) and the British Society for Antimicrobial Chemotherapy (BSAC).
I am also advisor to PhD students working on TB and cutaneous leishmaniasis.
- Drug discovery and development
- Drug resistance
- Cell biology
Disease and Health Conditions
- Infectious disease
- Neglected Tropical Diseases (NTDs)
- Leishmania donovani
- Pharmaceutical Industry
- pharmacokinetic - pharmacodynamic modelling
Snapshot profiling of anti-leishmanial potency of lead compounds and drug candidates against intracellular L. donovani amastigotes with focus on human derived host cells.
Koniordou, M. ; Patterson, S. ; Wyllie, S. ; Seifert, K. ;
Antimicrob Agents Chemother, 2017; 61(3)
Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate.
Seifert, K.; Juhls, C.; Salguero, F.J.; Croft, S.L.;
Antimicrob Agents Chemother, 2015; 59(9):5819-23
Structures, targets and recent approaches in anti-leishmanial drug discovery and development.
Seifert, K. ;
Open Med Chem J, 2011; 5:31-9
N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents.
Nicoletti, S.; Seifert, K.; Gilbert, I.H.;
Int J Antimicrob Agents, 2009; 33(5):441-8
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert, K.; Perez-Victoria, F.J.; Stettler, M.; Sánchez-Cañete, M.P.; Castanys, S.; Gamarro, F.; Croft, S.L.;
Int J Antimicrob Agents, 2007; 30(3):229-35
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert, K.; Croft, S.L.;
Antimicrob Agents Chemother, 2006; 50(1):73-9
Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.
Seifert, K.; DuchÃªne, M.; Wernsdorfer, W.H.; Kollaritsch, H.; Scheiner, O.; Wiedermann, G.; Hottkowitz, T.; Eibl, H.;
Antimicrob Agents Chemother, 2001; 45(5):1505-10
- → View all Karin Seifert 's publications